Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Quaker Recall Leads to Canada-Wide Class Action


VANCOUVER, BC, Jan. 19, 2024 /CNW/ - Slater Vecchio LLP has filed a class action lawsuit in British Columbia against The Quaker Oats Company and PepsiCo Canada ULC on behalf of all persons in Canada who purchased or claim to have fallen ill from consuming Quaker products that have been recalled due to potential Salmonella contamination.

On January 11, 2024, the Canadian Food Inspection Agency recalled thirty-eight Quaker products, including Quaker-branded granola and cereal products, due to possible Salmonella contamination. The Canadian Food Inspection Agency subsequently recalled over thirty yogurt and parfait products that contained recalled Quaker granola. A full list of the products recalled as of January 16, 2024 is accessible on the Government of Canada's recall database.

Sam Jaworski, a partner at Slater Vecchio LLP, stated, "Canadians trust manufacturers to produce packaged foods that can safely be consumed without the risk of illness from contamination. Through a class action, Canadians can access justice to hold suppliers accountable through strength in numbers, even if it would not be economical to pursue a lawsuit at the individual level."

If you suspect that you have fallen ill after eating a potentially contaminated product, seek medical attention as appropriate. If you have purchased but have not yet consumed a recalled product, follow Health Canada's guidance and either discard the product or return it to the location from where you purchased it.

Slater Vecchio LLP is seeking to identify individuals who fell ill from consuming a recalled product. Please submit your information on our website at https://www.slatervecchio.com/class-action/quaker-granoloa-salmonella-class-action/.

SOURCE Slater Vecchio LLP


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: